HighTower Advisors LLC Sells 1,216 Shares of Thermo Fisher Scientific Inc. $TMO

HighTower Advisors LLC lowered its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.8% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 145,039 shares of the medical research company’s stock after selling 1,216 shares during the quarter. HighTower Advisors LLC’s holdings in Thermo Fisher Scientific were worth $84,043,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of TMO. High Note Wealth LLC increased its stake in shares of Thermo Fisher Scientific by 170.6% in the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 29 shares in the last quarter. JPL Wealth Management LLC acquired a new position in Thermo Fisher Scientific during the 3rd quarter worth approximately $28,000. Beacon Financial Strategies CORP acquired a new position in Thermo Fisher Scientific during the 4th quarter worth approximately $29,000. Olistico Wealth LLC acquired a new position in Thermo Fisher Scientific during the 4th quarter worth approximately $29,000. Finally, Cloud Capital Management LLC acquired a new position in Thermo Fisher Scientific during the 3rd quarter worth approximately $31,000. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Up 0.9%

Shares of NYSE:TMO opened at $451.74 on Thursday. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $643.99. The company has a quick ratio of 1.15, a current ratio of 1.53 and a debt-to-equity ratio of 0.77. The business’s 50 day moving average is $482.22 and its 200 day moving average is $539.63. The stock has a market cap of $167.88 billion, a price-to-earnings ratio of 24.83, a PEG ratio of 1.98 and a beta of 0.88.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.25 by $0.19. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The business had revenue of $11.01 billion during the quarter, compared to the consensus estimate of $10.86 billion. During the same period in the prior year, the firm posted $5.15 EPS. The firm’s quarterly revenue was up 6.2% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 24.86 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, April 15th. Shareholders of record on Friday, March 13th were given a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend was Friday, March 13th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. Thermo Fisher Scientific’s payout ratio is currently 10.34%.

Analyst Ratings Changes

A number of research analysts recently weighed in on TMO shares. Royal Bank Of Canada set a $490.00 price target on Thermo Fisher Scientific and gave the stock a “sector perform” rating in a research note on Thursday, May 14th. Wells Fargo & Company dropped their price objective on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. TD Cowen dropped their price objective on shares of Thermo Fisher Scientific from $696.00 to $683.00 and set a “buy” rating on the stock in a research note on Friday, January 30th. Jefferies Financial Group raised shares of Thermo Fisher Scientific to a “strong-buy” rating in a research note on Friday, April 24th. Finally, Stifel Nicolaus dropped their price objective on shares of Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating on the stock in a research note on Friday, April 24th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $616.10.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 5,000 shares of the firm’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the completion of the sale, the chief executive officer directly owned 123,925 shares of the company’s stock, valued at $63,499,170. This trade represents a 3.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction on Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the sale, the chief operating officer directly owned 25,051 shares of the company’s stock, valued at approximately $11,590,095.66. This represents a 1.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.